Candel Therapeutics Inc (CADL) volume hits 1.39 million: A New Opening for Investors

Sana Meer

As on Thursday, Candel Therapeutics Inc (NASDAQ: CADL) started slowly as it slid -6.30% to $4.61, before settling in for the price of $4.92 at the close. Taking a more long-term approach, CADL posted a 52-week range of $3.79-$14.60.

The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded -43.86%. Meanwhile, its Annual Earning per share during the time was -43.86%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 75.98%. This publicly-traded company’s shares outstanding now amounts to $54.89 million, simultaneously with a float of $41.06 million. The organization now has a market capitalization sitting at $253.06 million. At the time of writing, stock’s 50-day Moving Average stood at $5.33, while the 200-day Moving Average is $6.08.

Candel Therapeutics Inc (CADL) Ownership Facts and Figures

Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. Candel Therapeutics Inc’s current insider ownership accounts for 25.21%, in contrast to 38.42% institutional ownership. According to the most recent insider trade that took place on Jul 28 ’25, this organization’s Chief Medical Officer sold 937 shares at the rate of 6.98, making the entire transaction reach 6,540 in total value, affecting insider ownership by 52,493. Preceding that transaction, on Jun 30 ’25, Company’s Chief Medical Officer sold 781 for 5.04, making the whole transaction’s value amount to 3,936. This particular insider is now the holder of 52,493 in total.

Candel Therapeutics Inc (CADL) Earnings and Revenue Records

Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.17 per share during the current fiscal year. Candel Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 75.98% and is forecasted to reach -0.91 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 37.47% through the next 5 years, which can be compared against the -43.86% growth it accomplished over the previous five years trading on the market.

Candel Therapeutics Inc (NASDAQ: CADL) Trading Performance Indicators

Let’s observe the current performance indicators for Candel Therapeutics Inc (CADL). It’s Quick Ratio in the last reported quarter now stands at 7.04.

In the same vein, CADL’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.69, a figure that is expected to reach -0.23 in the next quarter, and analysts are predicting that it will be -0.91 at the market close of one year from today.

Technical Analysis of Candel Therapeutics Inc (CADL)

Through scrutinizing the latest numbers posted by the [Candel Therapeutics Inc, CADL], it can be observed that its last 5-days Average volume of 0.75 million was lower the volume of 0.97 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 18.75% While, its Average True Range was 25.85.

Raw Stochastic average of Candel Therapeutics Inc (CADL) in the period of the previous 100 days is set at 5.38%, which indicates a major fall in contrast to 10.79% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.28 that was lower than 0.34 volatility it exhibited in the past 100-days period.

News Daemon
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.